

ADVERTISEMENT



ADDITIONAL VENTURES

AHA & Additional Ventures Collaborative Science Awards in Single Ventricle Heart Disease
Required pre-proposals due: **DECEMBER 19, 2023**
[LEARN MORE](#)

SCIENCE VOLUNTEER

WARNING SIGNS

Search



Advanced Search

DONATE

Circulation

Hello Guest!

MY ALERTS

SIGN IN

JOIN

OpenAthens/Shibboleth »

Submit your article



AHA Journals

Journal Information

All Issues

Subjects

Features

Resources & Education

For Authors & Reviewers

Home > Circulation > Vol. 124, No. suppl_21 > Abstract 15989: Eighteen Year Clinical and Echocardiographic Follow up of the Freestyle Stentless Bioprostheses

FREE ACCESS
MEETING REPORT

Tools Share

Jump to

Abstract

eLetters

CORE 6. CATHETER-BASED AND SURGICAL INTERVENTIONS

SESSION TITLE: CARDIAC SURGERY: VALVULAR HEART DISEASE (NOT INCLUDING PERCUTANEOUS VALVES)

Abstract 15989: Eighteen Year Clinical and Echocardiographic Follow up of the Freestyle Stentless Bioprostheses

Vincent Tchana-Sato, Francois Dagenais, Pierre Voisine, Jean Perron, Sandro Sponga, Daniel Doyle and Siamak Mohammadi

Originally published 26 Mar 2018 | Circulation. 2011;124-A15989

Abstract

Objectives: Stentless aortic bioprostheses were designed to provide enhanced hemodynamic performances and potentially greater longevity due to lower mechanical stress on the leaflets. The present report describes the outcomes of the Freestyle stentless aortic bioprostheses in a large single center cohort followed for up to 18 years.

Methods: Between January 1993 and May 2011, 430 patients underwent primary aortic valve replacement with a Freestyle stentless bioprosthesis in the subcoronary position with (n=146) or without (n=284) coronary bypass graft surgery. There were 233 men and 197 women with a mean age of 68.2±8.2 years. All Clinical and echocardiographic data were collected prospectively. Mean overall follow-up was 9.0±4.4 years (range: 0.1-18 years), and complete in all patients.

Results: Overall hospital mortality was 3.5% (n=15). Overall 10 and 15-year survival were 60.7% and 36.4%, respectively. Fifty patients required re-operation during follow-up: 28 for structural valve deterioration (SVD), 6 for endocarditis, 4 for severe mismatch and 12 for non-structural valve deterioration. Overall freedom from reoperation was 90.8% and 74.4% at 10 and 15 years, while freedom from reoperation for SVD was 95.9% and 82.1% at the same timepoints. At 10 and 15 years, freedom from reoperation for SVD was 93.7% and 64.0% for patients under 60 years of age, and 96.5% and 88.0% for patients with 60 years of age and older (p= 0.01). The median time to explantation for SVD was 10.7 years (range: 3.2-15.8-years). SVD presented mostly as severe aortic insufficiency (AI) due to leaflet tear (n=25/28; 89.3%). Freedom from moderate or more severe AI was 92.1% and 80.5% at 10 and 15 years respectively. The independent risk factors for reoperation for SVD were age > 60 years (1.9, CI: 1.6-2.5, p=0.001) and dyslipidemia (3.6, CI: 1.3-10.1, p= 0.01). Mean pressure gradient for the whole cohort at 10 and 15 years was 12.4 and 12.5 mm Hg.

Conclusion: Aortic valve replacement with the Freestyle stentless bioprostheses in a subcoronary position provides good long-term clinical and echocardiographic outcomes after 60 years of age. Severe aortic insufficiency with leaflet tear is the major mode of SVD leading to reoperation in these patients.

eLetters

eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its [Correspondence](#) page.

[Sign In to Submit a Response to This Article](#)
[Previous](#)
[Back to top](#)
[Next](#)
[Details](#)
[Related](#)
[References](#)
[Figures](#)

Circulation

November 22, 2011
Vol 124, Issue
suppl_21

ADVERTISEMENT

Publish Proudly With AHA Journals

Download Our Free Publishing Guide Today!

Article Information

[Article Metrics](#)
[View all metrics](#)
[Downloads](#)
[Citations](#)

No data available.

Total

© 2011 by American Heart Association, Inc.

Originally published March 26, 2018

[Check for updates](#)

Keywords

[Aortic valve](#)
[Surgery](#)
[Aortic diseases](#)
[Echocardiography](#)

ADVERTISEMENT

Trend Watch

Discover what research is popular with your peers

New collections every month

[Read Now!](#)

Circulation

AHA Journals

Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)

Circulation

Circ: Arrhythmia and Electrophysiology

Circ: Genomic and Precision Medicine

Circ: Cardiovascular Imaging

Circ: Cardiovascular Interventions

Circ: Cardiovascular Quality & Outcomes

Circ: Heart Failure

Circulation Research

Hypertension

Journal of the American Heart Association (JAHA)

Stroke

Stroke: Vascular and Interventional Neurology

AIM: Clinical Cases

Journal Information

[About Circulation](#)
[Editorial Board](#)
[Reprints](#)
[Customer Service and Ordering Information](#)
[AHA Journals RSS Feeds](#)
[For International Users](#)
[Institutions/Librarians FAQ](#)
[For Subscribers](#)
[Subscriber Help](#)
[Wolters Kluwer Privacy Policy](#)

Subjects

[All Subjects](#)
[Arrhythmia and Electrophysiology](#)
[Basic, Translational, and Clinical Research](#)
[Critical Care and Resuscitation](#)
[Epidemiology, Lifestyle, and Prevention](#)
[Genetics](#)
[Heart Failure and Cardiac Disease](#)
[Hypertension](#)
[Imaging and Diagnostic Testing](#)
[Intervention, Surgery, Transplantation](#)
[Quality and Outcomes](#)
[Stroke](#)
[Vascular Disease](#)

Features

[Bridging Disciplines](#)
[Circulation at Major Meetings](#)
[Special Themed Issues](#)
[Global Impact of the 2017 ACC/AHA Hypertension Guidelines](#)
[Circulation Supplements](#)
[Cardiovascular Case Series](#)
[ECG Challenge](#)
[Hospitals of History](#)
[On My Mind](#)
[Circulation on the Run Podcast](#)

Resources & Education

[AHA Guidelines and Statements](#)
[Circulation CME](#)
[Information for Advertisers](#)

For Authors & Reviewers

[Instructions for Authors](#)
[Submission Site](#)
[AHA Journals EDI Editorial Board](#)
[Author Reprints](#)


National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service
1-800-AHA-USA-1
1-800-242-8721

[Local Info](#)
[Contact Us](#)

ABOUT US

[About the AHA/ASA](#)
[Annual Report](#)
[AHA Financial Information](#)
[Careers](#)
[SHOP](#)
[Latest Heart and Stroke News](#)
[AHA/ASA Media Newsroom](#)
[Global Programs](#)

OUR SITES

[American Heart Association](#)
[American Stroke Association](#)
[Professional Heart Daily](#)
[More Sites](#)

TAKE ACTION

[Advocate](#)
[Donate](#)
[Planned Giving](#)
[Volunteer](#)

ONLINE COMMUNITIES

[AFib Support](#)
[Garden Community](#)
[Patient Support Network](#)

[Privacy Policy](#) |
 [Copyright](#) |
 [Ethics Policy](#) |
 [Conflict of Interest Policy](#) |
 [Linking Policy](#) |
 [Diversity](#) |
 [Careers](#) |
 [Suppliers & Providers](#) |
 [Accessibility Statement](#) |
 [State Fundraising Notices](#)

© American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is qualified 501(c)(3) tax-exempt organization. *Red Dress™ DHHS, Go Red™; AHA; National Wear Red Day® is registered trademark.


[Manage Cookie Preferences](#)